Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
about
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An updatemicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicityHow to Improve Therapeutic Ratio in Radiotherapy of HCCTissue- and Serum-Associated Biomarkers of Hepatocellular CarcinomaModulation of Autophagy by Sorafenib: Effects on Treatment ResponseMolecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesNew perspectives in glioblastoma antiangiogenic therapyMechanisms of ferroptosisSorafenib-induced Scrotal EczemaTargeting Wnt/β-catenin pathway in hepatocellular carcinoma treatmentMouse models of liver cancer: Progress and recommendationsCurrent and future treatments for hepatocellular carcinomaCurrent systemic treatment of hepatocellular carcinoma: A review of the literatureCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaUnderstanding the role of PIN1 in hepatocellular carcinomaCase analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenibModel-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicineNovel small molecule Raf kinase inhibitors for targeted cancer therapeuticsAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsEvidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesExpression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelComprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer through optical molecular imagingThe study of a novel sorafenib derivative HLC-080 as an antitumor agentDistinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3Ligand-target prediction by structural network biology using nAnnoLyzeSmall Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK SignalingERK2 mediates inner hair cell survival and decreases susceptibility to noise-induced hearing lossActivity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Extra-abdominal desmoid tumours: a review of the literature.Physical supports from liver cancer cells are essential for differentiation and remodeling of endothelial cells in a HepG2-HUVEC co-culture model.Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro studyPredicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.The acute transcriptomic and proteomic response of HC-04 hepatoma cells to hepatocyte growth factor and its implications for Plasmodium falciparum sporozoite invasion.
P2860
Q24619987-B5190A37-DCFD-4EFB-8ACB-C4316A3DDB93Q24620203-A17CDC66-984E-4ADC-A3B9-0602F4BCF740Q26738862-762BAB58-7CFC-4BF9-8B13-33815D1AEE2BQ26743361-337C6DA9-0712-4708-A24E-2EF7CFC52974Q26745320-E34780CD-9CF1-4192-BDD0-09D47FC41761Q26745338-1D2B2883-AA38-4E56-9BE6-AB0FF2091FF5Q26746028-1AFAA893-7495-4F68-8CD7-10F4152BA567Q26751418-93003B57-DBE5-4A52-8C2D-03CC210ABB8BQ26770144-E2864CCE-9139-46AC-892B-C98C4918EDF5Q26774623-B6446BBC-BC52-4BC8-BC52-29DC3DC48E82Q26799788-E876F4A8-C3E8-49DF-887B-8DB19106FE6FQ26801211-4431C159-7CCE-4BF7-8507-C47EEF197B01Q27026036-30E4AB54-3B5E-4844-BD2C-993DA330A9DAQ27853202-A73A2DC1-176B-4A4F-B9A6-1FDC89B84566Q28073477-A1B64B63-AD70-4971-8542-196B97216C2FQ28083400-E9A838A4-800F-4A7B-9C3B-C8BEE39192A5Q28087569-5017FE9D-C9F4-4A26-BE54-DA6E4235EA7AQ28265862-0FBF34CF-5364-4D32-8282-0E59FFBBB816Q28478344-C9B9655C-BB99-4A2F-A5E2-272AF78F6256Q28478709-6E0D97B0-3573-4F6B-9460-40AEDAD3B55EQ28488869-90890B8A-83CD-4BCC-86AC-B869B5CE0EADQ28535159-D3E9627C-8B1F-4165-A4DA-532C062E69E3Q28538538-CCAF1C86-055D-40B1-9BB1-4033F9801319Q28540521-BC32A065-435E-4830-A125-4DA9F810D4A2Q28542391-0CBDCD4F-9DB3-434F-9123-633460A37F79Q28545126-926AE1E0-6FE2-425E-87C5-5AC2832DD543Q28552433-CAF06F5E-CF4F-42BE-A37D-73C70BC663C6Q30398327-36A9D0C5-D214-4B8D-8C8A-386B8319E769Q30429122-4DEB37CD-5746-458C-8B83-E510640B9C6EQ30463805-5CF95286-285D-4AC3-9EDA-55EEBDA984A1Q30653607-95C57A8F-2D6F-4091-A90F-E36700000E17Q30834745-527CABEE-FAD6-475A-9F8C-E9B497D7701BQ33404877-7FC536F9-D351-4509-B59D-6489E6D6D921Q33410974-268B2837-7580-4032-A893-5A43344C0EDEQ33414998-85B8A192-57C1-4165-A80A-F0C7CB88B615Q33475230-8FFF8B67-4641-4AAA-9C49-F97FB1AC525DQ33495790-C280FA33-2B91-449F-AFA6-73559649F516Q33496309-1CC8794A-0786-4B9B-8B8F-F6D816B2FF83Q33509293-D310B9B5-24DC-4EF3-AF28-4498CF6F7774Q33583133-0527D862-40FD-4AA2-8C02-D76FA9FCD6D6
P2860
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.
@en
type
label
Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.
@en
prefLabel
Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.
@en
P2093
P1433
P1476
Sorafenib blocks the RAF/MEK/E ...... lar carcinoma model PLC/PRF/5.
@en
P2093
Angela McNabola
Charles Chen
Christopher Carter
Dean Wilkie
Mark Lynch
Scott Wilhelm
Xiaomei Zhang
Yichen Cao
P304
11851-11858
P356
10.1158/0008-5472.CAN-06-1377
P407
P577
2006-12-01T00:00:00Z